Skip to Main content Skip to Navigation
Journal articles

DPP-4 inhibitors in the treatment of type 2 diabetes.

Abstract : Although being a primary objective in the management of type 2 diabetes, optimal glycaemic control is difficult to achieve and usually not maintained over time. Type 2 diabetes is a complex pathology, comprising altered insulin sensitivity and impaired insulin secretion. Recent advances in the understanding of the physiological functions of incretins and their degrading enzyme dipeptidyl-peptidase (DPP)-4 have led to the 'discovery' of a new class of oral anti-diabetic drugs. Several DPP-4 inhibitors (or gliptins) with different chemical structures are now available. These agents inhibit the degradation of the incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and hence potentiate glucose-dependent insulin secretion. DPP-4 inhibitors inhibit DPP-4 activity by almost 100% in vitro, maintaining a ≥ 80% inhibition throughout the treatment period in vivo, thus prolonging GLP-1 half-life, and significantly reducing HbA1c generally by -0.7 to 0.8% as well as fasting and post-prandial glycaemia. They are well-tolerated with no weight gain and few adverse effects, and, of particular interest, no increase in hypoglycaemic episodes. Although different by their chemical structure and pharmacokinetic properties, the DPP4 inhibitors currently available have proven similar glucose lowering efficacy.
Document type :
Journal articles
Complete list of metadatas

Cited literature [101 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00659269
Contributor : Marie-Hélène Derudas <>
Submitted on : Thursday, January 12, 2012 - 2:39:20 PM
Last modification on : Wednesday, October 21, 2020 - 3:41:59 AM
Long-term archiving on: : Friday, April 13, 2012 - 2:31:52 AM

Files

Duez_et_al._DPP4inhibitors_MSt...
Files produced by the author(s)

Identifiers

Citation

Hélène Duez, Bertrand Cariou, Bart Staels. DPP-4 inhibitors in the treatment of type 2 diabetes.. Biochemical Pharmacology, Elsevier, 2012, 83 (7), pp.823-32. ⟨10.1016/j.bcp.2011.11.028⟩. ⟨inserm-00659269⟩

Share

Metrics

Record views

638

Files downloads

4617